Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vernalis -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2)	6/27/2005 5:19:50 AM
From: tuck	Read Replies (1) \| Respond to of 20

Interim frovatriptan results for prevention of menstrually related migraine: Message 21452255 We're only crossing posts for Nigel . . . "Nigel just needs this helping hand . . ." Edit: Just noticed that last PR said they had enough cash for three years. How/when did they get that/What did I miss? Edit2: Good God, this thing's basically been basing for two bloody years! finance.yahoo.com With that much cash and possible market expansion for Frova next year, this could be a sleeper hit? What's your take on it know? Cheers, Tuck